Hemostasis And Tissue Sealing Agents Market Size, Share & Trends Market Analysis By Product (Topical Hemostat, Adhesive & Tissue Sealant), By Region (Europe, APAC, North America), And Segment Forecasts, 2023 - 2030

Hemostasis And Tissue Sealing Agents Market Size, Share & Trends Market Analysis By Product (Topical Hemostat, Adhesive & Tissue Sealant), By Region (Europe, APAC, North America), And Segment Forecasts, 2023 - 2030

Hemostasis And Tissue Sealing Agents Market Growth & Trends

The global hemostasis and tissue sealing agents market size is expected to reach USD 14.47 billion by 2030, registering a CAGR of 8.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. The agents have gained popularity over time due to their ability to prevent blood loss. The rapid growth of minimally invasive technology and the demand for faster recovery by patients are expected to promote market growth over the forecast period. According to the Centers for Disease Control and Prevention (CDC), approximately 150 million of the American population are currently suffering from at least one chronic condition, which leads to surgeries and even mortality at times.

An estimate over the rising incidence was made by the CDC, which concluded that over 48% of the entire American population is expected to suffer from chronic conditions. The market is expected to witness lucrative growth over the next seven years owing to an increase in product demand supported by the rising surgery volumes. Growth in the geriatric population and the prevalence of chronic conditions are also among the key factors driving the market. In December 2019, the Ethicon, a unit of Johnson & Johnson, launched its protein spray for blood-stopping, designed to quickly & efficiently control and seal off excessive bleeding during minimally invasive procedures and open surgeries.

During the COVID-19 pandemic, severe cases among patients infected by the virus have shown the tendency to develop septic shock and Acute Respiratory Distress Syndrome (ARDS), demanding special care in ICU, with residual chronic disability and poor long-term results. Among these patients in the ICU, Coagulopathy has been commonly noticed indicating underlying diseases and organ dysfunction. This has been one of the major contributing factors to the increasing demand for hemostasis & tissue sealing products.

Hemostasis And Tissue Sealing Agents Market Report Highlights

• The market growth can be attributed to a rise in the global volume of surgeries and the applicability of the product across a variety of surgeries to avoid the occurrence of hypovolemic shock, thrombocytopenia, blood transfusions, and postoperative complications
• The topical hemostat segment accounted for the largest revenue share of 67.2% in 2022. In addition, a segment is expected to grow at the fastest CAGR of 9.2% during the forecast period due to its use with conventional treatment to provide cost-efficiency, quick & easy absorbability of the hemostatic agent, minimal tissue reactivity, and non-antigenicity.
• The adhesive & tissue sealant segment is expected to grow at a CAGR of 8.1% over the forecast period. Adhesives and tissue sealants are crucial in controlling blood loss during surgical procedures and function by binding with and sealing the damaged tissues.
• North America dominated the market and accounted for the largest revenue share of 33.1% in 2022, owing to the growing prevalence of cardiovascular disorders, diabetes, and cancer within the region.

Please note The report will be delivered in 2-3 business days upon order notification.